3/26
09:00 am
sgmt
Sagimet Biosciences (SGMT) is now covered by Rodman & Renshaw. They set a "buy" rating and a $28.00 price target on the stock.
High
Report
Sagimet Biosciences (SGMT) is now covered by Rodman & Renshaw. They set a "buy" rating and a $28.00 price target on the stock.
3/14
01:32 am
sgmt
Low
Report
3/11
01:40 pm
sgmt
Sagimet Biosciences (SGMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
Low
Report
Sagimet Biosciences (SGMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
3/11
08:04 am
sgmt
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Low
Report
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
3/11
07:30 am
sgmt
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Medium
Report
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
3/3
05:48 pm
sgmt
Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript [Seeking Alpha]
Low
Report
Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript [Seeking Alpha]
3/1
07:02 pm
sgmt
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. [Yahoo! Finance]
Low
Report
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. [Yahoo! Finance]
2/25
07:18 am
sgmt
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences [Yahoo! Finance]
2/25
07:00 am
sgmt
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Medium
Report
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
2/5
07:00 am
sgmt
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
High
Report
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
2/3
08:03 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
2/3
08:00 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.
2/2
07:00 am
sgmt
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
High
Report
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
1/30
08:41 am
sgmt
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
High
Report
Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
1/29
07:41 am
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.
1/29
06:00 am
sgmt
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
High
Report
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
1/29
06:00 am
sgmt
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
High
Report
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
1/27
07:02 pm
sgmt
Sagimet Biosciences (NASDAQ:SGMT) was given a new $8.00 price target on by analysts at Barclays PLC.
Medium
Report
Sagimet Biosciences (NASDAQ:SGMT) was given a new $8.00 price target on by analysts at Barclays PLC.
1/9
06:11 am
sgmt
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference [Yahoo! Finance]
1/8
07:00 am
sgmt
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Low
Report
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference